Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events
Item 8.01. Other Events.

As previously disclosed in its Current Report on Form 8-K dated June 16, 2017, Interpace Diagnostics Group, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC, as representative (the “Representative”) of the several underwriters named therein, in connection with a public offering of the Company’s securities. to the Underwriting Agreement, the Company had granted the Representative a 45-day option to purchase up to an additional 1,875,000 shares of common stock, $.01 par value (“Common Stock”), and/or 1,875,000 warrants (the “Warrants”) to purchase Common Stock to cover over-allotments. The Representative previously exercised such option in part to purchase the Warrants. On July 28, 2017, the Representative exercised such option to purchase an additional 875,000 shares of Common Stock the (“Additional Shares”) at a price of $1.09 per share. The closing for the Additional Shares occurred on July 31, 2017, resulting in gross proceeds of $953,750 to the Company, before underwriting discounts and commissions.

About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.